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ABSTRACT 
Oxidative stress has been described as a putative disease mechanism in 
pathologies associated with an elevation of homocysteine. An increased reactive oxygen 
species (ROS) production and apoptosis rate have been associated with several 
disorders of cobalamin metabolism, particularly with methylmalonic aciduria combined 
with homocystinuria cblC type. In this work, we have evaluated several parameters 
related to oxidative stress and apoptosis in fibroblasts from patients with 
homocystinuria due to defects in the MTR, MTRR and MTHFR genes involved in the 
remethylation pathway of homocysteine. We have also evaluated these processes by 
knocking down the MTRR gene in cellular models, and complementation by transducing 
the wild-type gene in cblE mutant fibroblasts. All cell lines showed a significant 
increase in ROS content and in MnSOD expression level, and also a higher rate of 
apoptosis with similar levels to the ones in cblC fibroblasts. The amount of the active 
phosphorylated forms of p38 and JNK stress-kinases was also increased. ROS content 
and apoptosis rate increased in control fibroblasts and in a glioblastoma cell line by 
shRNA-mediated silencing of MTRR gene expression. In contrast, wild-type MTRR 
gene corrected mutant cell lines showed a decrease in ROS and apoptosis levels. To the 
best of our knowledge, this study provides the first evidence that an impaired 
remethylation capacity due to low MTRR and MTR activity might be partially 
responsible for stress response. 
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INTRODUCTION 
Remethylation disorders are rare inherited metabolic diseases of enzymes 
involved in the remethylation of homocysteine to methionine causing homocystinuria. 
They include defects in methionine synthase (MTR, OMIM ID: 156570), methionine 
synthase reductase (MTRR, OMIM ID: 602568) and MMADHC (OMIM ID: 611935) 
proteins corresponding to cblG, cblE and cblD-variant 1 cobalamin complementation 
groups respectively; and in 5,10-methylene tetrahydrofolate reductase enzyme 
(MTHFR, OMIM ID: 236250) [Watkins and Rosenblatt, 2011]. MTR protein is a 
methylcobalamin-dependent enzyme that catalyzes the successive transfer of a methyl 
group from 5-methyltetrahydrofolate to the cob(I)alamin form of the cofactor and from 
methylcobalamin to homocysteine to form methionine and tetrahydrofolate as products 
[Watkins et al., 2002] (Fig. 1). Activity of MTR depends on the presence of a second 
protein, MTRR, which reductively reactivates oxidized MTR and functions to maintain 
it in an active form [Leclerc et al., 1998]. When cobalamin becomes oxidized, MTRR 
catalyzes its reductive methylation, using S-adenosylmethionine (SAM) as a methyl 
donor to regenerate methylcobalamin (Fig. 1). SAM is an important methyl donor for 
many other cellular processes including DNA methylation, neurotransmitter synthesis 
and phospholipid metabolism. MTHFR is a cytosolic enzyme that catalyzes the 
reduction of 5,10-methylene tetrahydrofolate to 5-methyl tetrahydrofolate, the primary 
form of folate, which is utilized for homocysteine remethylation to methionine [Watkins 
and Rosenblatt, 2011] (Fig. 1).  
Biochemically, these disorders are characterized by homocysteine elevation and 
low-to-normal methionine levels, without urinary methylmalonic acid excretion. 
Patients present severe clinical symptoms which are mainly neurological for MTHFR 
deficiency and neurohematological for cblE and cblG defects [Watkins and Rosenblatt, 
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2011]. The features vary with age of onset that ranges from the neonatal period to 
adulthood. Patients with neonatal disease exhibit acute neurological distress. Children 
and adults may experience acute or rapidly progressive neurological deterioration 
[Schiff et al., 2011]. To date, the biochemical goal for treatment of remethylation 
disorders is to decrease plasma homocysteine levels and to increase plasma methionine 
levels by augmenting residual methionine synthase activity with B12. Vitamins B9 and 
B6 as well as betaine and methionine supplementation can also be provided to improve 
metabolic parameters [Schiff et al., 2011]. 
Two major mechanisms have been proposed to explain the pathogenesis of these 
diseases: i) defective methionine synthesis (with a consequent drop in SAM production 
and deficiencies of numerous methylation reactions leading to hypomyelination in the 
central nervous system) [Surtees, 1998] and ii) hyperhomocysteinemia or 
homocystinuria. MTHFR deficient mice exhibited hyperhomocysteinemia and 
decreased methylation capacity, with neuropathology and aortic lipid deposition [Chen 
et al., 2001; Chen et al., 2005]. MTRR knockout mice presented metabolic derangement 
of methionine and folate metabolism [Elmore et al., 2007]. 
Elevated homocysteine concentration has been proposed as a risk factor for 
numerous diseases, including neural tube defects, cardiovascular diseases and a range of 
neurodegenerative conditions [Zou and Banerjee, 2005]; and it has been suggested to 
induce neurological dysfunction via oxidative stress [Ho et al., 2001; James et al., 
2004]. In addition, an increased reactive oxygen species (ROS) production and 
apoptosis induction in neurons [Zou et al., 2010], and in several tissues such as bone 
and vascular endothelium have been described due to elevated levels of homocysteine 
[Kim et al., 2006; Koh et al., 2006; Perna et al., 2003]. Our previous data support the 
role of oxidative stress in the pathophysiology of defects in cobalamin metabolism, 
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especially from patients with isolated methylmalonic aciduria (MMA) cblB type 
[Richard et al., 2007; Richard et al., 2006] and with MMA combined with 
homocystinuria (MMACHC) cblC type [Jorge-Finnigan et al., 2010; Richard et al., 
2009]. We have also shown differences between cblB and cblC patient cells regarding 
the apoptosis rate and preferred apoptotic pathway: apoptosis appears to be mainly 
triggered through the extrinsic pathway in cblC, while the intrinsic pathway was 
primarily activated in cblB cells [Jorge-Finnigan et al., 2010]. Taking these observations 
into account, we hypothesized that homocysteine might be responsible for the 
differences observed between cells from patients with MMA (cblB type) and with 
MMACHC (cblC type) and might have a relevant role in oxidative stress and apoptosis 
processes in patients with these inherited metabolic diseases, as has been described in 
other diseases.  
In order to study a different metabolic disorder in which homocysteine has a 
relevant role and to gain better insights into its pathophysiology, the purpose of this 
study has been to analyze several parameters related to stress response in fibroblasts 
from patients with homocystinuria caused by defects in the remethylation pathway 
along with the evaluation of these processes by knocking down the MTRR gene in 
cellular models and by expressing this gene in mutant cells. The data indicate that the 
impaired remethylation capacity in patients might be at least partly responsible for 
enhancing ROS and apoptosis levels. 
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MATERIALS AND METHODS 
SAMPLES 
The study included available fibroblasts from three patients belonging to cblE 
group (P1, P2 and P3) and one to cblG (P4); and from a patient with defects in the 
MTHFR gene (P5). Patients presented a high concentration of homocysteine in plasma 
(>100 µmol/l). Patients were referred from clinics to be biochemically and/or 
genetically diagnosed at Centro de Diagnóstico de Enfermedades Moleculares 
(CEDEM) in Madrid.  Relevant clinical and molecular data about individual patients 
included in this study are detailed in Table 1. Genetic analysis of the family members 
showed that changes cosegregated in the respective families. The uniparental disomy 
causing homozygosity for the pathogenic mutation identified in P1 has been recently 
described [Pérez et al., 2012]. Skin fibroblasts from four controls (GM08333 (C1), 
GM08680 (C2), GM08429 (C3) and GM03348 (C4)) aged 2-10 years were obtained 
from Coriell Cell Repositories (NJ, USA). Fibroblast cultures were established from 
patient skin biopsies and cultivated according to standard procedures [Richard et al., 
2007]. Assays were performed when the culture reached 75 to 85% confluence. Control 
and patient fibroblast cells were between passages 7 and 10. U87 human glioblastoma 
and SH-SY5Y human neuroblastoma cell lines were maintained in DMEM containing 
10% FCS. Primary cultures of neurons from mice cortex were provided by Dr. F. 
Hernández, UAM, Madrid, Spain. Written informed consent to be included in this study 
was obtained from all subjects or their parents/legal guardians. Ethical approval for the 
use of human samples in the study was granted by the Ethics Committee of the 
Universidad Autónoma de Madrid.  
ROS AND APOPTOSIS ASSAYS 
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Intracellular ROS and apoptotic cells were detected and quantitated by flow 
cytometry in fibroblasts as described [Richard et al., 2009]. 
Mitochondrial superoxide was detected using the red MitoSOXTM indicator 
(Invitrogen, Carlsbad, CA, USA). Cells were incubated with 5 µM MitoSOXTM  for 10 
min at 37ºC, protected from light. The measurements were carried out using  
FACSCantoII (BD Biosciences, San Jose, CA, USA). 
WESTERN BLOT ANALYSIS 
Total protein extracts were obtained from fibroblasts and glioblastoma cells for 
mitochondrial superoxide dismutase (MnSOD) and MTRR protein expression analysis 
as described [Richard et al., 2006]. For immunoblotting detection, samples (20 µg total 
protein extracts) were loaded onto 4-12% NuPAGE Novex Bis-Tris mini gels 
(Invitrogen) and blotted onto nitrocellulose membranes using iBlot Dry Blotting system 
(Invitrogen). Western Blotting was carried out using anti- MnSOD (Enzo Life Science, 
PA, USA) diluted 1:5000 and anti-MTRR polyclonal antibody (Aviva Systems Biology, 
San Diego, CA, USA) diluted 1:1000. The stripped blots were reprobed with anti-α-
tubulin antibody (1:5000, Cell Signaling Technology, Inc., Danvers, MA, USA). Anti-
rabbit (MnSOD and MTRR detection) and anti-mouse (α-tubulin detection) secondary 
antibodies were used as IgG-horseradish peroxidase conjugated and were detected by 
Enhanced Chemiluminescence (GE, Healthcare, Berkshire, UK).  
The activation of p38 and JNK stress kinases was analysed by Western Blot as 
previously described [Jorge-Finnigan et al., 2010]. The expression pattern of 
phosphorylated p38 and JNK proteins was individually normalized by the protein 
expression of total p38 and total JNK proteins which include both the phosphorylated 
(active) and unphosphorylated (inactive) forms. 
shRNA/LENTIVIRUS INFECTION 
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Lentivirus incorporating shRNAs were generated in HEK293T packaging cells 
by cotransfection with pLKO.1 plasmid containing shRNA sequences (Sigma-Aldrich, 
St. Louis, MO, USA), packing plasmid pCMV-dR8.74, and envelope plasmid pMD2.G 
(both kindly provided by Dr. J. Diaz-Nido, UAM, Madrid, Spain) using lipofectamine 
and Plus reagent (Invitrogen, Carlsbad, CA, USA). Medium containing viral particles 
(non-target control shRNA (SHC002) or either of the MTRR shRNAs targeting different 
sequences of human MTRR) was harvested at 48 h after transfection and used to infect 
control fibroblasts with 4 µg/ml polybrene and U87 glioblastoma cells. Successfully 
infected cells were selected and maintained with 1 μg/ml puromycin (Sigma-Aldrich). 
shRNA clone information: clone TRC number: TRCN0000035404, TRCN0000035405, 
TRCN0000035406 and TRCN0000035407; clone ID: NM_002454.1-285s1c1, 
NM_002454.1-1310s1c1, NM_002454.1-1818s1c1 and NM_002454.1-549s1c1; clone 
sequence in http://www.sigmaaldrich.com/catalog/mission/SHCLNG-
NM_002454?lang=es&region=ES).   
REAL-TIME PCR 
Total RNA was isolated from control fibroblasts and U87 glioblastoma cells 
using MagNA Pure Compact RNA Isolation kit and MagNA Pure Compact instrument 
(Roche Applied Science, Mannheim, Germany). Samples were quantitated 
spectrophotometrically at 260 nm using the Nanodrop ND-1000 photometer (Thermo 
Scientific, Wilmington, MA, USA). The optimal design of the real-time PCR primers 
and the Universal ProbeLibrary probe selection was performed using ProbeFinder 
software (Roche Applied Science). RT-PCR was performed using 
GeneAmpPCRSystem9700 (Applied Biosystems, Carlsbad, CA, USA), and real-time 
PCR was performed using LightCycler 480 (Roche Applied Science), both from Unidad 
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de Genómica, Parque Científico de Madrid, UAM, Madrid, Spain. Amplification 
efficiency and sample-to-sample variation were normalized by monitoring GAPDH. 
EXPRESSION OF HUMAN MTRR cDNA IN FIBROBLAST CELLS 
Wild-type MTRR cDNA was cloned into a green fluorescent protein (GFP)-
expressing pEZ-Lv201-lentiviral vector (EX-T8826-Lv201) (Source BioScience 
LifeSciences, Cambridge, UK). The empty lentiviral vector expressing GFP alone was 
used as control. Lentiviruses were generated by transient co-transfection with the 
lentiviral vectors, pCMV-dR8.74 and pMD2.G plasmids using lipofectamine and Plus 
reagent (Invitrogen) in HEK293T packaging cells. Lentiviruses encoding both GFP and 
MTRR proteins, or GFP alone were used to infect fibroblasts from P2 and P3 cblE 
patients. GFP expression in infected cells was ~70-90%, therefore GFP expressing-cells 
were not sorted. Mitochondrial superoxide and apoptosis assays were performed in the 
total cell population, but data analysis of these assays were carried out in GFP-positive 
cells also expressing MTRR protein. 
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RESULTS 
Several parameters related to oxidative stress and cell death were evaluated in 
fibroblasts from 5 patients with homocystinuria (Table 1). First, we examined ROS 
levels in control and patient fibroblasts by flow cytometry (Table 2). There was a ~3-
fold increase in ROS production in fibroblasts from all patients (Fig. 2A). We also 
evaluated the expression pattern of the mitochondrial MnSOD by Western Blot 
analysis. As shown in Figure 2B, the expression of MnSOD protein was increased in 
patient cells (~3-5-fold by densitometric analysis). 
 We next analysed the percentage of annexin V-positive apoptotic cells in patient 
fibroblasts. Flow cytometry analysis demonstrated elevated levels of annexin V-positive 
apoptotic cells (~2-3-fold) suggesting an increased basal level of apoptosis (Table 2 and 
Fig. 3A). Particularly, cblE patient P2 showed a three-fold increase compared to 
controls. 
The activation of two proteins belonging to the mitogen-activated protein kinase 
(MAPK) superfamily, p38 kinase and Jun N-terminal kinase (JNK) was investigated by 
immunoblotting (Fig. 3B). A significantly increased expression of phospho-p38 and 
phospho-JNK (active forms) was detected in patient fibroblasts. Quantitative 
densitometric analysis demonstrated a 1.5-3-fold higher expression for phospho-p38; 
and a lower activation of JNK (1.2-2.5-fold) in patient cells compared to controls. 
We also applied shRNA technology to stably knock down MTRR gene 
expression in control fibroblasts, as a representative gene involved in the remethylation 
pathway of homocysteine. After infection of control fibroblasts with lentivirus 
containing four different MTRR shRNAs or control shRNA and puromycin selection, 
we successfully obtained MTRR silenced cells in which their growth was not affected 
negatively in comparison to the non-target shRNA control. qRT-PCR was performed to 
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confirm gene-silencing effects at the mRNA level (Fig. 4A). The different MTRR 
shRNAs resulted in reductions of 70% for shRNA04, 85% for shRNA05, 35% for 
shRNA06 and 45% for shRNA07. In addition, Western Blot technique showed a 
significant decrease in MTRR protein expression especially in shRNA04 and shRNA05 
cells (Fig. 4B). To demonstrate if MTRR gene silencing has an effect in oxidative stress, 
we analysed ROS content in MTRR shRNA and non-target shRNA control cells by flow 
cytometry. Interestingly, the results showed that ROS levels are increased in those 
shRNA cells in which MTRR mRNA expression is highly reduced (shRNA04 and 
shRNA05) (Fig. 4C). Next, we analysed the percentage of annexin V-positive apoptotic 
cells in MTRR-silenced fibroblasts. shRNA06 and shRNA07 cells showed a low level of 
apoptosis. In contrast, shRNA04 and shRNA05 fibroblasts showed a 1.5-fold increase 
in apoptosis compared to control cells (Fig. 4D). 
To examine the MTRR-silencing effect in other cellular models, MTRR protein 
expression was first analysed in U87 glioblastoma and SH-SY5Y neuroblastoma human 
cell lines. MTRR expression was detectable in U87 glioblastoma however we could 
detect no expression of the protein in neither neuroblastoma cells nor neuronal mice 
cells (data not shown), suggesting a probable glial expression of MTRR protein. In view 
of these observations, we then examined stable shRNAs knockdown of MTRR gene 
expression in U87 glioblastoma cells for ROS and apoptosis analysis. The efficiency of 
MTRR knockdown in stable MTRR shRNA glioblastoma cells was assessed at mRNA 
and protein levels by qRT-PCR and Western Blot analysis respectively. Three of the 
four MTRR shRNAs efficiently reduced MTRR mRNA and protein levels compared 
with vector control cell lines (shRNA04, shRNA05 and shRNA07) (Fig. 5A, B). To 
study the mechanisms regulating the effects of MTRR knockdown on ROS and 
apoptosis function in this cellular model, we examined once more the fluorescence of 
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H2DCFDA and annexin V probes by flow cytometry. Stable shRNAs knockdown of 
MTRR significantly increased ROS levels (Fig. 5C) and apoptosis rate (Fig. 5D). 
shRNA04 and shRNA05 glioblastoma cells showed the highest increase in ROS and 
apoptosis levels compared with vector shRNA control cells (~2-fold). 
It is worth noting that the use of four different MTRR shRNAs has defined our 
study since cells infected with those MTRR shRNAs that provided the highest silencing 
of the gene, also induced the highest elevation of ROS and apoptosis levels in both 
fibroblast and glioblastoma cellular models. 
Homocysteine levels were also measured in cell culture medium from MTRR 
shRNA fibroblasts and glioblastoma cells. We found an increase of ~1.5-fold of 
homocysteine in those shRNA cells´ medium in which the MTRR gene expression was 
highly reduced (see the Supplementary Table 1 for more details). 
Finally, to verify if the loss of function of MTRR is related to the observed 
oxidative stress and apoptosis, we analysed these processes in two cblE patient cells 
infected with the wild-type MTRR cDNA using a lentiviral vector. Mean fluorescence 
intensity measurement by flow cytometry of mitochondrial superoxide MitoSOX probe 
showed a decrease in superoxide anion levels in the infected cells expressing MTRR 
protein compared to the infected cells expressing GFP alone. ROS levels were 
significantly reduced in P3 (37%) and slightly reduced in P2 (15%) mutant fibroblasts 
expressing MTRR protein (Fig. 6A). In addition, annexin V-positive apoptotic cells 
were decreased in the infected cells expressing MTRR protein compared to the infected 
cells expressing GFP alone. Apoptosis rate was decreased ~20% in P2 and P3 cblE 
mutant cells expressing MTRR protein (Fig. 6B). 
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DISCUSSION 
 
Homocystinuria is caused by inborn metabolic defects in the transsulphuration 
or remethylation pathways of homocysteine. Remethylation defects are inherited 
metabolic diseases characterized by defective methionine synthesis and homocystinuria. 
The pathogenesis of these disorders is far from being understood; a reduced supply of 
methionine and SAM, or some other downstream metabolites, and an elevation of 
homocysteine have been proposed as the major pathophysiological mechanisms.  
Elevation of homocysteine has also been correlated with complex and 
multifactorial diseases, including neural tube defects, cardiovascular and 
neurodegenerative diseases. Several hypotheses have been proposed, including 
oxidative stress, endoplasmic reticulum stress, and alterations in signal transduction 
pathways and activation of inflammatory factors to explain the mechanisms underlying 
homocysteine mediated-pathophysiology of these diseases [Zou and Banerjee, 2005]. 
Homocysteine is readily oxidized in plasma to form homocystine and homocysteine 
mixed disulfides, representing the predominant forms of this amino acid in circulation 
[Zou and Banerjee, 2005], and it can also undergo autooxidation causing the disruption 
of redox homeostasis in vascular and neuronal cells [Obeid and Herrmann, 2006]. This 
oxidation has been correlated with ROS generation. Homocysteine can stimulate ROS 
formation in a number of different cell types, such as splenic B lymphocytes [Zhang et 
al., 2001], mesangial cells [Yang and Zou, 2003], monocytes [Zeng et al., 2003] and 
vascular smooth muscle cells [Liu et al., 2008]. Several reports have shown that 
homocysteine induces neuronal apoptosis by increasing levels of cytosolic calcium and 
ROS formation in neurons which may be a putative disease mechanism in 
neurodegenerative disorders [Zou et al., 2010]. Our previous results from the study of 
several parameters of oxidative stress and apoptosis in fibroblasts from patients with 
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defects in cobalamin metabolism revealed that cblB and cblC groups presented the 
highest ROS and apoptosis levels [Richard et al., 2007; Richard et al., 2009]. Both 
groups accumulate the toxic methylmalonic acid in mitochondria; whereas the cblC 
group, apart from this organic acid, accumulates the cytosolic metabolite homocysteine. 
These observations encouraged us to continue the research in patients with 
homocystinuria. We have shown a ROS over-production and an increased apoptosis 
level in fibroblasts from all patients with homocystinuria studied in this work (cblE, 
cblG and MTHFR deficiency).  These observations along with the recent study in 
plasma of patients with classical homocystinuria [Vanzin et al., 2011] suggest that 
oxidative stress might participate, at least in part, in the pathophysiology of 
homocystinuria. The over-expression of a marker of mitochondrial ROS production, 
MnSOD protein, was also found in fibroblasts from patients with homocystinuria which 
may be a compensatory mechanism that counteracts the consequences of elevated ROS 
levels, as has been reported in other disorders [Filosto et al., 2002; Hu et al., 2005; 
Kunishige et al., 2003; Ohkoshi et al., 1995], in a Mut-knockout mice liver [Chandler et 
al., 2009] and in cells from different MMA patients [Richard et al., 2007]. Similarly, as 
compensatory mechanism increased levels of the antioxidant glutathionine resulting 
from the elevation of homocysteine has been described [Mosharov et al., 2000]. In 
addition, the increase in ROS and apoptosis levels in stable MTRR-silenced control 
fibroblasts and glioblastoma cell line, and the decrease of these levels in MTRR gene 
corrected mutant cells lines suggest that the impaired remethylation due to low MTRR 
and MTR activity may play a relevant role in these processes.  
Our study of the activation of essential signaling proteins, such as p38 and JNK 
which belong to the mitogen-activated protein kinases (MAPKs) family [Temkin and 
Karin, 2007] has provided essential information about the signal transduction pathways 
 15
that could be involved in the pathogenesis of homocystinuria. The activation of p38 and 
JNK kinases in cells from patients with this disease revealed a stimulation of these 
stress-sensing pathways which could be correlated with elevated ROS levels. The same 
has been described for endothelial cells, where MAPKs (p38), ERK1/2 and NF-kB 
signaling pathways were activated by homocysteine-induced ROS [Zou and Banerjee, 
2005]. Homocysteine promoted also a rapid increase in phosphorylation of p38 MAPK 
in microglia [Zou et al., 2010], in vascular smooth muscle cells [Akasaka et al., 2005] 
and monocytes [Zeng et al., 2003]. 
Neurological damage has been reported in patients with homocystinuria, and 
numerous studies in recent years have investigated the role of homocysteine as a cause 
of brain damage. Several studies have explored homocysteine transport in the brain: it 
may be produced within the brain itself [Obeid and Herrmann, 2006]; and it may cross 
the blood-brain barrier probably in both directions [Kamath et al., 2006]. The 
neurotoxic effects of homocysteine have been described in several studies [Obeid and 
Herrmann, 2006], and homocysteine has been found to induce neurological dysfunction 
via oxidative stress [Ho et al., 2001; James et al., 2004]. Children with cystathionine β-
synthase (CBS) deficiency (>100 µM of homocysteine) have shown a 10-fold increase 
in the concentration of homocysteine in cerebrospinal fluid [Surtees et al., 1997]. It is 
interesting to note that fibroblasts from a CBS deficient patient, with defects in the 
transsulphuration homocysteine pathway, also showed high ROS and apoptosis levels 
[Richard et al., 2009]. Further studies are needed to evaluate stress response in more 
CBS patients. Presumably, the pathophysiological mechanisms underlying neurological 
impairment are different between remethylation and transsulphuration deficiencies. 
Further analysis will provide a deeper insight into the effect of homocysteine and other 
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metabolites in the activation of apoptosis and/or ROS production in homocystinuria 
disorders.    
Finally, the cytotoxicity of homocysteine has been reported to be mitigated by 
antioxidants like N-acetyl cysteine, vitamin E or C [Ho et al., 2001; Reis et al., 2002; 
Wyse et al., 2002]. Interestingly, a number of epidemiological studies have found a link 
between antioxidant uptake and a reduced incidence of dementia in Alzheimer’s disease 
[Grundman et al., 2002]. Our promising results will be followed up with further studies 
focused on using antioxidants as a novel approach for treatment of homocystinuria 
metabolic diseases. The administration of exogenous antioxidants should be evaluated 
as tools for optimizing therapies because the outcome of these pathologies might be 
improved in an early intervention. 
In summary, we provide the first evidence that cells from homocystinuria 
patients with defects in the remethylation pathway showed high ROS and apoptosis 
levels. Moreover, p38 and JNK MAPKs might be activated in a ROS-dependent manner 
in these patients which could be responsible for apoptosis activation. Cell dysfunction 
and death due to oxidative stress may contribute in part to the pathogenesis of these 
inherited metabolic disorders.  
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FIGURE LEGENDS 
Figure 1. Remethylation pathway of homocysteine. MTRR: methionine synthase 
reductase, responsible for the cblE disorder; MeCbl: methylcobalamin; MTR: 
methionine synthase, affected in the cblG disorder; MTHFR: methylene 
tetrahydrofolate reductase; SAM: S-adenosylmethionine; SAHCy: S-
adenosylhomocysteine. 
Figure 2. Analysis of intracellular ROS levels and MnSOD protein expression in 
control and patient fibroblasts. (A) ROS content was determined by flow cytometry 
using H2DCFDA as a fluorescence probe. Results are expressed as DCF fluorescence 
relative to control cells. Control value was determined as the mean of data from the four 
control cell lines. Data represent mean values ± standard deviation from at least three 
independent experiments, each one performed by triplicate (**P<0.01). (B) Equal 
amounts from the four controls and patients were loaded (20 µg of total cell lysates) and 
subjected to Western Blotting with anti-MnSOD antibody. The bottom panel shows the 
stripped blots reprobed with anti-α-tubulin antibody to ensure equal amounts of protein 
loaded in each lane. This result is representative of three independent experiments. 
Protein quantification was performed by laser densitometry. The ratios between 
MnSOD/α-tubulin for each cell line were calculated to determine the expression fold-
change relative to controls. Data represent mean ± SD of three independent experiments 
(*P< 0.05; **P<0.01). (A and B) Patients along with the complementation groups they 
belong to are depicted in the figure. C: control; P: patient. 
Figure 3. Analysis of apoptosis and phosphorylated p38 and JNK stress-activated 
protein kinases expression in control and patient fibroblasts. (A) Percentage of 
annexin V-positive apoptotic cells in patient and control cells relative to total cell 
number per sample by flow cytometry. Control value was determined as the mean of 
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data from the four control cell lines. Data represent mean ± standard deviation of three 
independent experiments, each one performed by triplicate (*P< 0.05; **P<0.01). (B) 
Equal amounts from the four controls and patients were loaded (20 µg of total cell 
lysates) and subjected to immunoblotting with anti-phosphorylated p38 and anti-
phosphorylated JNK antibodies. The stripped blots were reprobed with total anti-p38 
and total anti-JNK antibodies as evidence of the equivalent amounts of protein loaded in 
each lane. The results in each case are representative of at least three independent 
experiments. Protein quantification was performed by laser densitometry. The ratios 
between phosphorylated/total kinase forms for each cell line were calculated to 
determine the activation fold-change relative to controls. Data represent mean ± SD of 
three independent experiments (*P< 0.05; **P<0.01). (A and B) Patients along with the 
complementation groups they belong to are depicted in the figure. C: control; P: patient. 
Figure 4.  Results of shRNA knockdown in control fibroblasts. (A) Quantification 
of MTRR mRNA expression by qRT-PCR. Quantities are shown as % MTRR mRNA 
expression relative to fibroblasts infected with non-target control shRNA (shRNAc). 
The data represent mean ± standard deviation of three independent experiments. (B) 
Analysis of MTRR protein expression by Western Blot. 50 µg of total cell lysates 
were loaded and subjected to immunoblotting with anti-MTRR antibody. The bottom 
panel shows the stripped blot reprobed with anti-α-tubulin antibody to ensure equal 
amounts of protein loaded in each lane. (C) Detection of intracellular ROS levels. 
ROS content was determined by flow cytometry using H2DCFDA as fluorescence 
probe. Results are expressed as DCF fluorescence relative to non-target control shRNA 
(shRNAc). Data represent mean values ± standard deviation from at least two 
independent experiments, each one performed by triplicate (*P<0.05). (D) Apoptosis 
detection by flow cytometry. Percentage of annexin V-positive apoptotic cells in 
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MTRR shRNAs and non-target control shRNA (shRNAc) relative to total cell number 
per sample. Data represent mean ± standard deviation of two independent experiments, 
each one performed by triplicate (*P< 0.05). (A, B, C and D) shRNA04, shRNA05, 
shRNA06 and shRNA07 indicate MTRR shRNAs targeting different sequences of 
human MTRR used in this study for the generation of lentiviral particles and infection of 
fibroblasts (see Materials and Methods). 
Figure 5. Results of shRNA knockdown in U87 glioblastoma cells. (A) 
Quantification of MTRR mRNA expression by qRT-PCR. Quantities are shown as 
% MTRR mRNA expression relative to U87 cells infected with non-target control 
shRNA (shRNAc). The data represent mean ± standard deviation of three independent 
experiments. (B) Analysis of MTRR protein expression by Western Blot. 50 µg of 
total cell lysates were loaded and subjected to immunoblotting with anti-MTRR 
antibody. The bottom panel shows the stripped blot reprobed with anti-α-tubulin 
antibody to ensure equal amounts of protein loaded in each lane. (C) Detection of 
intracellular ROS levels. ROS content was determined by flow cytometry using 
H2DCFDA as fluorescence probe. Results are expressed as DCF fluorescence relative to 
non-target control shRNA (shRNAc). Data represent mean values ± standard deviation 
from at least two independent experiments, each one performed by triplicate (*P<0.05; 
**P<0.01).  (D) Apoptosis detection by flow cytometry. Percentage of annexin V-
positive apoptotic cells in MTRR shRNAs and non-target control shRNA (shRNAc) 
relative to total cell number per sample. Data represent mean ± standard deviation of 
two independent experiments, each one performed by triplicate (*P< 0.05; **P<0.01). 
(A, B, C and D) shRNA04, shRNA05, shRNA06 and shRNA07 indicate the MTRR 
shRNAs targeting different sequences of human MTRR used in this study for the 
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generation of lentiviral particles and infection of U87 glioblastoma cells (see Materials 
and Methods). 
Figure 6. Mitochondrial superoxide and apoptosis analysis in infected cblE patient 
cells expressing MTRR protein. (A) Mitochondrial superoxide detection by flow 
cytometry. Oxidative stress was measured by a mean intensity of fluorescence of 
MitoSOX in each infected cells expressing MTRR protein respect to the same cell line 
expressing GFP alone. Data represent mean ± standard deviation of three independent 
experiments, each one performed by triplicate (*P< 0.05; **P<0.01). (B) Apoptosis 
detection by flow cytometry. Percentage of annexin V-positive apoptotic cells in 
infected cells expressing MTRR protein and GFP alone relative to total cell number per 
sample. Data represent mean ± standard deviation of three independent experiments, 
each one performed by triplicate (*P< 0.05). 
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